On August 25, CANSINOBIO rose 6.15% in regular trading, trading at HK$28.74/share, with turnover of HK$168 million. The stock rebounded after consecutive sessions of decline following its approximately 48.59% single-day surge on August 20.

On the news front, Bocom International issued a report stating that China's domestic mRNA vaccine enterprises are at a post-pandemic trough, with the industry severely undervalued overall. The broker noted that R&D success and indication expansion of comparable overseas products are expected to drive investment sentiment recovery and valuation repair for companies including CANSINOBIO. CLSA previously highlighted that the company's development route and antigen design are broadly similar to Moderna's, with key differentiation in its three-component lipid nanoparticle delivery system, which may support stronger cellular immune responses. The stock had pulled back over 13% across August 21 and 24 on profit-taking after the initial mRNA-driven rally sparked by Moderna and Merck's landmark Phase 3 mRNA cancer vaccine success.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)